Royalty Pharma Financing Cash Flow increased by 9.0% to -$272.67M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 71.0%, from -$941.30M to -$272.67M.
Negative values often indicate a company is paying down debt or returning capital to shareholders, while positive values may indicate external financing.
The net result of all cash inflows and outflows related to financing activities, including debt issuance, debt repayment...
Highly dependent on the company's current capital structure and lifecycle stage compared to industry peers.
net_cash_from_financing| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$224.42M | $1.03B | -$220.97M | -$228.25M | -$230.09M | -$265.55M | -$210.37M | -$347.00M | -$1.36B | -$231.89M | -$212.00M | $1.16B | -$941.30M | -$507.81M | -$299.60M | -$272.67M |
| QoQ Change | — | +560.9% | -121.4% | -3.3% | -0.8% | -15.4% | +20.8% | -64.9% | -291.8% | +82.9% | +8.6% | +645.6% | -181.4% | +46.1% | +41.0% | +9.0% |
| YoY Change | — | — | — | -1.7% | -122.2% | — | +4.8% | -52.0% | -490.9% | +12.7% | -0.8% | +433.3% | -344.0% | -143.9% | — | +71.0% |